Adverse events and reactions related to cryopreservation of stem cell products during the COVID-19 pandemic
Blood & Tissue
|
14/05/2020
The Federal Office for Safety in Health Care received a document and various links by the Dutch authority regarding adverse events and reactions related to cryopreservation of stem cell products during the COVID-19 pandemic.
https://www.ebmt.org/covid-19-and-bmt
https://share.wmda.info/pages/viewpage.action?pageId=344866320#/
https://network.bethematchclinical.org/news/nmdp/be-the-match-response-to-covid-19/updates-for-transplant-centers-and-cooperative-registries/#Cryopreservation
https://wmda.info/professionals/promoting-donor-care/adverse-events-searspear/
https://www.ebmt.org/sites/default/files/2018-06/FACT-JACIE%207th%20Edition%20Standards.pdf
https://www.celltherapyjournal.org/article/S1465-3249(19)30870-9/fulltext
Further inquiry note
Page last modified:
14/05/2020